Comprehensive Evaluation of Adherence to Therapy, Its Associations, and Its Implications in Patients With Chronic Myeloid Leukemia Receiving Imatinib

Unnikrishnan, Radhika; Veeraiah, Surendran; Mani, Samson; Rajendranath, Rejiv; Swaminathan, Rajaraman; Elangovan, Grace Sahaya Vidhubala; Radhakrishnan, Venkatraman; Ganesan, Trivadi S.; Sagar, Tenali Gnana; Ganesan, Prasanth

doi:10.1016/j.clml.2016.02.040

Cited by 38 publications

(42 citation statements)

References 23 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Other quantitative studies using a questionnaire found percentages of nonadherent CML patients ranging from 0% to 47%. 11,12,19,23,30,[34][35][36][37][38][39][40][41] Differences in the extent of nonadherence in studies are a well-known phenomenon in adherence research and relate to the drug, follow-up period and differences in measurement and calculation of adherence. 9,42 In the present study, a self-composed question was used to measure nonadherence ("How often do you not take your CML medicine?").…”

Section: Discussionmentioning

confidence: 99%

“…9,42 In the present study, a self-composed question was used to measure nonadherence ("How often do you not take your CML medicine?"). In the other studies, 11,12,19,23,30,[34][35][36][37][38][39][40][41] alternative questionnaires were used to measure medication adherence. Although the differences in measurements make it difficult to compare the results of studies, it is clear that a considerable number of CML patients have difficulties with adhering to their medication regimen.…”

Section: Discussionmentioning

confidence: 99%

“…Adequate provision of information has been positively related to medication adherence in CML. 11,19,23,28,30,34,37 To fulfil patients' needs for information, HCPs should provide information in a structured way and adapted to the possibilities of the individual patient to understand information and encourage patients to ask questions.…”

Section: Discussionmentioning

confidence: 99%

See 2 more Smart Citations

Needs for information and reasons for (non)adherence in chronic myeloid leukaemia: Be aware of social activities disturbing daily routines

Boons

Harbers

Timmers

et al. 2018

European J of Haematology

View full text Add to dashboard Cite

Nonadherence to CML medication does not cause concern in all patients and is not discussed pro-actively. HCP have a clear role in supporting medication adherence in CML and must be aware that social activities disturbing daily routines contribute to nonadherence. HCP should discuss (non)adherence in a direct manner, motivate patients to play an active role in managing their medication and timely provide extensive and understandable information on all aspects of CML.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Needs for information and reasons for (non)adherence in chronic myeloid leukaemia: Be aware of social activities disturbing daily routines

Boons

Harbers

Timmers

et al. 2018

European J of Haematology

View full text Add to dashboard Cite

show abstract

“…The direct link between patient self-reported QoL and poor adherence to therapy has also been recently reported. 41 In the modern era of TKIs, one of the key goals of therapy is to keep patients' QoL within satisfactory levels for as long as possible. The main risk of not being aware of how satisfied our patients are with their own QoL, and the real burden of the symptoms that they can tolerate, is not promptly identifying those patients who might be at heightened risk of poor adherence behavior.…”

Section: How Should We Measure Pros In CML Clinical Research?mentioning

confidence: 99%

The value of quality of life assessment in chronic myeloid leukemia patients receiving tyrosine kinase inhibitors

Efficace

Cannella

2016

Hematology

View full text Add to dashboard Cite

The development of the oral tyrosine kinase inhibitors (TKIs) to treat chronic myeloid leukemia (CML) is one of the great triumphs of cancer research. Although the efficacy of TKIs has dramatically improved the disease-specific overall survival rate, the prevalence of CML is increasing worldwide. Currently, CML patients receive prolonged (even lifelong) treatment, and over the last decade, clinical decision making has become challenging. Therefore, consideration of the effects of TKI therapies on patients' quality of life (QoL) and symptom burden (ie, patient-reported outcomes [PROs]) is now critical to more robustly inform patient care and improve health care quality. Over the last 5 years, a number of studies have generated valuable PRO data, for example, on long-term QoL effects of imatinib therapy or symptom burden of patients switching from imatinib to second-generation TKIs. PRO findings are important, as they provide a unique patient perspective on the burden of the disease and treatments effects. We will review main evidence-based data on the use of PROs in clinical research and highlight the importance of methodological rigor of PRO assessment. Also, we will describe the potential value of using PRO assessment in routine clinical practice, for example, to facilitate timely management of side effects. Areas for future research will also be discussed. Learning Objectives• List main evidence-based data on the impact of tyrosine kinase inhibitors on patients' quality of life and symptom burden • Describe the value of quality of life assessment in CML clinical research • Illustrate the importance of integrating quality of life assessment into routine practice and the relationship between quality of life assessment and adherence to therapy

show abstract

“…Современные рекомендации для пациентов с ХМЛ говорят о том, что необходимо продолжать лечение ИТК независимо от результатов глубокого молекулярного ответа [20]. Однако при долгосрочном применении ИТК могут возникать осложнения, что приведет к нерегулярному их применению, это связано с более низким КЖ [47,49].…”

unclassified

Quality of Life in Patients With Myeloproliferative Neoplasms (Review)

Давыдкин¹,

Попельнюк²,

Наумова³

et al. 2019

SSMJ

View full text Add to dashboard Cite

Comprehensive Evaluation of Adherence to Therapy, Its Associations, and Its Implications in Patients With Chronic Myeloid Leukemia Receiving Imatinib

Cited by 38 publications

References 23 publications

Needs for information and reasons for (non)adherence in chronic myeloid leukaemia: Be aware of social activities disturbing daily routines

Needs for information and reasons for (non)adherence in chronic myeloid leukaemia: Be aware of social activities disturbing daily routines

The value of quality of life assessment in chronic myeloid leukemia patients receiving tyrosine kinase inhibitors

Quality of Life in Patients With Myeloproliferative Neoplasms (Review)

Contact Info

Product

Resources

About